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Epigenetic loss of the RNA decapping enzyme NUDT16
mediates C-MYC activation in T-cell acute lymphoblastic
leukemia
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It is possible that the occurrence of intrinsic defects in RNA
processing pathways, such as RNA decapping,1–3 contribute to the
distorted RNA landscapes of cancer cells. After transcription by
RNA polymerase II, RNA molecules are equipped with a 5´-end
N7-methyl guanosine (m7G)-cap. This m7G-cap is essential for
translation, stabilizing the RNA molecule and protecting it from
exonucleolytic breakdown.1–3 For RNA decay to occur the
m7G-cap ﬁrst needs to be removed. This process is known as
decapping.1–3 The decapping mRNA 2 (DCP2) enzyme,4 also
known as the nucleoside diphosphate-linked moiety X motif
20 (NUDT20), was originally thought to be the only mammalian
RNA decapping enzyme with multiple cofactors controlling
its activity.1–3 DCP2 is a member of the Nudix superfamily of
hydrolase proteins, which predominantly catalyze the hydrolysis
of a wide range of small nucleotide substrates composed of a
nucleoside diphosphate linked to another moiety X.5 Another
Nudix member, nudix hydrolase 16 (NUDT16), has recently been
shown also to have mRNA decapping activity.6–8
Although genetic defects in DCP2 and NUDT16 have not been
reported, transcriptional silencing by promoter CpG island
hypermethylation is another mechanism for inactivating genes
in human cancer.9 Thus, we studied whether DNA methylation-
associated silencing of these RNA decapping enzymes occurred in
tumorigenesis. We ﬁrst screened a collection of 1001 human
cancer cell lines in which we have recently determined the DNA
methylation status of 450 000 CpG sites10 for the presence
of DCP2 and NUDT16 promoter CpG island methylation
(Supplementary Methods). The DCP2 promoter-associated CpG
island was found unmethylated in the vast majority of cell lines,
with a few examples of hypermethylated CpGs without enrich-
ment in any speciﬁc cell type (Supplementary Table S1). In
contrast, the NUDT16 promoter CpG island was methylated in
73% (19 of 26) of the T-cell-derived leukemia and lymphoma cell
lines included in the studied set (Supplementary Table S1;
Figure 1a). Data mining from microarray expression results10
showed that NUTD16 hypermethylation was associated with
transcript downregulation (Figure 1a). Genomic data available at
the COSMIC database (http://cancer.sanger.ac.uk/cosmic) did not
show the presence of NUDT16 mutations and deletions in the
mentioned cell lines. Beyond T-cell-derived malignancies, NUDT16
promoter CpG island was found mostly to be unmethylated in all
the other tumor types available in our data set, with the exception
of osteosarcoma (6 of 40, 15%), B-cell-derived leukemia and
lymphoma (8 of 60, 13.3%), and myeloid-derived malignancies (3
of 41, 7.3%; Supplementary Table S1; Figure 1a). The NUDT16 and
DCP2 promoter CpG islands were unmethylated in all the normal
human tissues studied, including T-lymphocytes isolated from
healthy individuals (Supplementary Figure S1).
Having found the aforementioned NUDT16 CpG island methy-
lation proﬁles, we studied in greater detail their association with
the possible transcriptional inactivation of the NUDT16 gene at
the RNA and protein levels in leukemia cell lines. We ﬁrst
performed bisulﬁte genomic sequencing of mutiple clones in the
T-cell Acute Lymphoblastic Leukemia (T-ALL) cell lines CCRF-CEM,
Jurkat, MOLT-4 and MOLT-16 using primers that encompassed the
transcription start site-associated CpG island and conﬁrmed the
hypermethylated status of the 5′-end region of NUDT16 in
comparison to normal T lymphocytes (Figure 1b), validating the
DNA methylation patterns obtained by the microarray approach
(Supplementary Figure S2). In contrast, normal T lymphocytes, the
T-ALL cell lines KOPN-8, REH and RS4;11 and the leukemia cell
lines HL-60 and K562 derived from myeloid lineage were all found
to be unmethylated (Figure 1b; Supplementary Figure S2). Most
notably, the NUDT16-hypermethylated T-ALL cell lines CCRF-CEM,
Jurkat, MOLT-4 and MOLT-16 minimally expressed the NUDT16
RNA transcript, as determined by quantitative real-time PCR
(Figure 1c), and protein, as assessed by western blot (Figure 1c).
Conversely, T-ALL cell lines unmethylated at the NUDT16
promoter (KOPN-8, REH and RS4;11) or unmethylated leukemia
cell lines from myeloid lineage (HL-60 and K562) expressed
NUDT16 RNA and protein (Figure 1c). Treatment of the T-ALL
methylated cell lines with the DNA-demethylating agent 5-aza-2-
deoxycytidine restored NUDT16 expression (Figure 1c).
We also sought to demonstrate that the NUDT16 hypermethy-
lation was not a speciﬁc feature of in vitro-grown T-ALL cell lines
and that it also occurred in primary T-ALL patients. Herein, we
performed methylation-speciﬁc PCR analyses to determine the
NUDT16 CpG island methylation status in 51 primary T-ALLs
(Supplementary Figure S2). We observed NUDT16 promoter CpG
island hypermethylation in 60.7% (31 of 51) of these T-ALL cases.
We did not ﬁnd any correlation between NUDT16 CpG island
methylation status and the clinicopathological characteristics of
the studied primary T-ALLs (Supplementary Table S2). NOTCH1
mutations were observed in 30% (12 of 40) of T-ALL patients
where additional DNA was available for further testing
(Supplementary Figure S3), and we did not observe any
association with the NUDT16 methylation status (Supplementary
Table S2). We did not detect any mutation in the CNOT3 gene
(Supplementary Figure S4). Supplementary Table S3 shows the
NUDT16 methylation and NOTCH1 mutational status, and the
clinicopathological characteristics for each one of the studied
T-ALL patients. RNA was available for ﬁve T-ALL samples, including
one methylated case. Using quantitative real-time PCR, NUDT16
expression was found in the four unmethylated samples, whereas
the NUDT16-hypermethylated sample did not show detectable
transcript levels (Supplementary Figure S5). Data mining of
a small set of primary T-ALL cases interrogated by another DNA
methylation microarray platform and expression microarrays
(Supplementary Methods) conﬁrmed our results by showing that
NUDT16 hypermethylation occurred in 58.8% (10 of 17) of cases
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in association with transcript downregulation (Supplementary
Figure S5).
Once we had shown the presence of NUDT16 CpG island
hypermethylation-associated transcriptional loss in T-ALL, we
studied its contribution to the leukemogenic phenotype in vitro
and in vivo. We ﬁrst analyzed the effect of the restoration of
NUDT16 expression in the T-ALL-hypermethylated cell lines
MOLT-4 and MOLT-16. Upon efﬁcient transduction of NUDT16,
we observed a signiﬁcant reduction in cellular growth measured
by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay in comparison with empty vector-
transduced cells (Figure 2a; Supplementary Figure S6). These
in vitro data were then translated to an in vivo model. We tested
the ability of NUDT16-transduced MOLT-4 and MOLT-16 cells to
form subcutaneous tumors in nude mice compared with empty
vector-transduced cells. T-ALL cells with restored expression of
NUDT16 showed lower tumorigenicity than MOLT-4 and MOLT-16
empty vector-derived tumors, as shown by measuring the increase
in tumor volume (Figure 2a; Supplementary Figure S6). Tumor
samples obtained at the end point of the subcutaneous nude
mouse experiment showed that tumor weights and volumes of
the NUDT16-transduced cells were lower than those observed
in empty vector-transduced cells (Figure 2a; Supplementary
Figure S6).
Finally, we wondered about the molecular mechanisms
involved in the anti-leukemogenic phenotype mediated by
NUDT16. In this regard, it is possible that the epigenetic defect
of NUDT16 can prevent the decapping and subsequent decay of
target RNAs involved in cellular transformation. To address this,
we ﬁrst studied the intracellular localization of the NUDT16
protein using nuclear compared with cytoplasmic fractioning
followed by western blot. NUDT16-hypermethylated leukemia cell
lines (CCRF-CEM, Jurkat, MOLT-4 and MOLT-16), as expected,
showed no evidence of the protein either in the cytosolic or the
nuclear compartments (Figure 2b). However, in unmethylated
leukemia cell lines (KOPN-8, HL-60 and K562), the NUDT16 protein
was present exclusively in the cytosolic fraction, as expected for an
RNA decapping enzyme (Figure 2b). Notably, MOLT-4 cells in
which we restored NUDT16 expression, upon transduction,
mimicked the pattern of NUDT16-unmethylated cells by expres-
sing the protein in the cytosolic fraction (Supplementary
Figure S7). We next sought to identify those RNA targets
Figure 1. DNA methylation-associated transcriptional silencing of NUDT16 in transformed cells. (a) Percentage of NUDT16 methylation in the
Sanger panel of cancer cell lines by tumor type. Tumor type sample sizes studied: T-cell-derived leukemia and lymphoma (n= 26),
osteosarcoma (n= 40), B-cell-derived leukemia and lymphoma (n= 57), myeloid-derived malignancies (n= 35), soft tissue sarcoma (n= 20),
kidney (n= 28), autonomic ganglia (n= 31), lung (n= 163), and other tumor types (n= 602). Right, NUDT16 methylation is associated with loss
of the transcript in the T-cell derived cell lines from Sanger. The box plots illustrate the distribution of expression values; the central solid line
indicates the median; the limits of the box show the upper and lower percentiles. Mann–Whitney U-test, ***Po0.0001. (b) Bisulﬁte genomic
sequencing of NUDT16 promoter CpG Island. CpG dinucleotides are represented as short vertical lines and the transcription start site (TSS) is
represented as a long black arrow. Eight single clones are shown for each sample. Presence of a methylated or unmethylated cytosine is
indicated by a black or a white square, respectively. (c) Top, expression levels of the NUDT16 transcript determined by real-time reverse
transcription PCR. Data shown represent mean± s.d. of biological triplicates; below, expression levels of the NUDT16 protein determined by
western blot; right, the expression of the NUDT16 RNA transcript was restored in the CCRF-CEM, Jurkat, MOLT-4 and MOLT-16 cells by
treatment with the demethylating drug 5-aza-2’-deoxycytidine. Data shown represent the mean± s.d. of biological triplicates.
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that avoided the normal decapping in our hypermethylated
T-ALL model. To accomplish this, we performed the RNA-
immunoprecipitation of m3G/m7G-capped transcripts11 in empty
vector compared with NUDT16-transduced MOLT-4 cells, followed
by hybridization of the immunoprecipitated RNA to an RNA
expression microarray (Supplementary Methods; Supplementary
Table S4). The expression microarray data have been deposited in
the Gene Expression Omnibus (GEO) repository under Accession
Number GSE84973. Among the set of transcripts derived from the
RNA-immunoprecipitation experiment that were found to be
decreased upon NUDT16 restoration in MOLT-4 cells, and thus
putative direct substrates of the decapping activity of the enzyme,
we found many genes with known anti-apoptotic or pro-
proliferative activities, such as BCL11A, MAP3K2 and GSK3B, and
the diminished stability of these transcripts upon NUDT16
transduction observed in microarrays was validated by quantita-
tive real-time PCR (Supplementary Figure S7). However, our
attention was particularly caught by the presence of the
transcripts for FBXO2812 and USP37,13 two proteins that, through
altered ubiquitylation, stabilize C-MYC, a key oncogene in the
natural history of T-ALL.14,15 We observed that the restoration of
NUDT16 expression in MOLT-4 cells reduced the levels of both the
RNA transcripts in Actinomycin D-treated cells (Figure 2c), and the
western blot assays showed a reduction in levels of the FBXO28
and USP37 proteins upon NUDT16 transduction (Figure 2c). Most
notably, the decay of the FBXO28 and USP37 transcripts upon
NUDT16 restoration in MOLT-4 cells was also associated with a
reduction in C-MYC protein levels (Figure 2c), the target of their
ubiquitylation-related activities. Similar results were found in the
MOLT-16 cell line where NUDT16 transduction reduced FBX028
levels (even in the absence of Actinomycin D; Supplementary
Figure S8), decreased C-MYC ubiquitylation12 and diminished
C-MYC protein levels (Supplementary Figure S8), supporting that
the loss of FBXO28-dependent MYC ubiquitylation results in
enhanced protein degradation, as it has been reported.12
Furthermore, Actinomycin D treatment results in almost a
complete loss of the C-MYC protein (Supplementary Figure S8).
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Figure 2. NUDT16 exerts growth-inhibitory effects and destabilizes mRNA targets that regulate MYC protein stability. (a) Top, restoration of
NUDT16 protein expression upon stable transduction in MOLT-4 cells (NUDT16-OE) was associated with reduced viability in the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay in comparison to empty vector-transduced cells. Probabilities are
those from permutation test; middle, tumor volume monitoring of xenograft samples derived from NUDT16 MOLT-4 cells transduced with
NUDT16 or the empty vector. ***Po0.001, **Po0.01. Restoration of NUDT16 expression was associated with smaller tumors; below, weight
and volume of the tumors excised at 60 days. Both measures were lower in the xenografts derived from MOLT-4 derived cells transduced with
NUDT16. Probabilities are those associated with Student’s t-tests. Results are presented as the mean± s.e.m., n= 10. (b) Nuclear/cytoplasmic
fractionation of NUDT16-methylated (CCRF-CEM, Jurkat, MOLT-4 and MOLT-16) and NUDT16-unmethylated (HL-60, K562 and KOPN-8) cell
lines show expression and cytosolic accumulation of NUDT16 in the unmethylated cells. Purity of fractions was assayed with the nuclear
protein β-Tubulin and the cytosolic Lamin-β. WCL, Whole Cell Lysate. (c) Left, validation of the mRNA expression levels by RT-qPCR following
the Actinomycin D treatment of the RNA-immunoprecipitation-derived candidates FBXO28 and USP37 in NUDT16 or empty vector-
transduced MOLT-4 cells. Restoration of NUDT16 expression destabilizes both mRNAs; middle, western blot assays conﬁrm reduction of
FBXO28 and USP37 protein expression upon NUDT16 transduction in MOLT-4 cells; right, western blot shows that the diminished FBXO28 and
USP37 levels upon NUDT16 restoration are also associated with a decrease in their target, the C-MYC protein.
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Overall, our data suggest the existence in T-ALL of a disrupted
RNA decapping pathway, mediated by the DNA methylation-
associated loss of NUDT16, which contributes to the natural
history of the disease by stabilizing transforming factors, such as is
the case of the leukemogenic protein C-MYC.
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Gain in the short arm of chromosome 2 (2p+) induces gene
overexpression and drug resistance in chronic lymphocytic
leukemia: analysis of the central role of XPO1
Leukemia (2017) 31, 1625–1629; doi:10.1038/leu.2017.100
Chronic lymphocytic leukemia (CLL), the most common adulthood
leukemia, is characterized by an accumulation of abnormal CD5+ B
lymphocytes in the peripheral blood, bone marrow and secondary
lymphoid organs. Acquired genetic mutations play an important
role in CLL pathogenesis, and massive parallel sequencing
identiﬁed new recurrently mutated genes such as NOTCH1,
S3FB1, XPO1, MYD88, EGR2 and NFKBIE.1–4 In addition, frequent
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